



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

To

Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

To

BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai - 400001

Date: August 25, 2026

Symbol: BALPHARMA

Scrip Code: 524824

Sub: Clarification with respect to tentative timeline for utilization of net proceeds of Preferential Issue

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is in continuation of the Company's earlier intimations made in connection with the allotment of Convertible Warrants on a preferential basis, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In this regard, the Company hereby clarifies that the timeline for utilisation of the net proceeds / tenure of the Convertible Warrants is 18 months from the date of allotment, in accordance with the applicable provisions of Regulation 162 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and is subject to receipt of the requisite in-principle approval from the Stock Exchanges.

Accordingly, the Company hereby confirms that there is no change in the objects of the Preferential Issue or the manner of utilisation of the proceeds. The present intimation is being made only to clarify the tentative timeline for utilisation of the net proceeds in view of the 18-month tenure of the Convertible Warrants.

Kindly take the above information on record.

Thanking You.

For Bal Pharma Ltd



Shreepada ML

Company Secretary and Compliance officer

ICSI M No : A66681